Choi, P., Bradbury, C., Gonzalez-Lopez, T. J., Ar, M. C., Trautmann-Grill, K., Rummel, M., Borchiellini, A., Cooper, N., Chuliber, F., Patell, R., Sanchez, B., Urban, P., Allepuz, A., Gac, F. L., Lin, R., Kuter, D. (2025). Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy. Blood. https://doi.org/10.1182/blood-2025-844